Clinical Trial Update: Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CHOP chemotherapy in combination with Campath (alemtuzumab) for T-cell lymphoma, NK-cell lymphoma, and other non-Hodgkin lymphomas; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer Cell Lymphoma
• Non-hodgkin Lymphoma
• T-cell Lymphoma

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Vincristine (vincristine)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: T-Cell Lymphoma, Lymphoma, Non-Hodgkin's | Phase 1 | Status: COMPLETED